Regulatory Compliance

PMET Resources Refiles CV5 Lithium Study After AMF Compliance Review

Image
PMET Resources Refiles CV5 Lithium Study After AMF Compliance Review

Montreal – October 03, 2026 -- PMET Resources Inc. has filed an amended NI 43-101 technical report for its Shaakichiuwaanaan lithium project in Quebec, correcting compliance irregularities flagged by Quebec's securities regulator without altering the underlying economics of its 2025 feasibility study.

AMF routine review triggers formatting and disclosure corrections

The Autorité des marchés financiers, acting under its continuous disclosure review program, identified issues requiring clarification in the original October 2025 technical report. PMET addressed qualified persons' certificates content, map scaling errors, disclosure on reasonable prospects for economic extraction of caesium, tantalum and gallium, and the cut-off grade methodology for caesium oxide. The company filed the corrected version on SEDAR+ with an unchanged effective date of October 03, 2026, an issue date of October 03, 2026, and an amended date of October 03, 2026.

CME Group Pulls Plans for 24/7 10-Barrel Crude Oil Futures Contract

Chicago – October 03, 2026 -- CME Group has withdrawn its regulatory filing to launch a 10-Barrel Crude Oil futures contract designed for round-the-clock trading, citing unresolved concerns from industry participants over unintended market risk.

CME Group abandons bid to counter unregulated 24/7 oil trading venues

The exchange operator had proposed the small-denomination contract as a transparent, CFTC-regulated alternative to 24/7 energy products already trading on other platforms, including onshore prediction markets and offshore perpetual futures. CME Group Chairman and CEO Terry Duffy said these existing products target retail participants and operate around the clock despite offshore perpetuals being illegal for U.S. participants, who nonetheless access them via virtual private networks.

FDA Approves Lilly's Jaypirca as First-Line CLL/SLL Therapy

Image
FDA Approves Lilly's Jaypirca as First-Line CLL/SLL Therapy

Indianapolis – October 03, 2026 -- The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly and Company's Jaypirca (pirtobrutinib), clearing the non-covalent BTK inhibitor as a first-line treatment for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletion.

Phase 3 trial data show an 80% reduction in disease progression risk

The approval rests on the BRUIN CLL-313 trial, which randomized 282 treatment-naïve patients 1:1 to pirtobrutinib or bendamustine plus rituximab (BR) chemoimmunotherapy. At a median follow-up of 28 months, pirtobrutinib cut the risk of disease progression by 80% versus BR (HR=0.20; 95% CI, 0.11–0.37; p0.0001). Median progression-free survival was not yet reached in the pirtobrutinib arm, compared with 33.5 months for BR.

California Discloses $40.1B in UC, Community College Payroll Data

Image
California Discloses $40.1B in UC, Community College Payroll Data

Sacramento – October 02, 2026 -- California State Controller Malia M. Cohen released 2025 self-reported payroll data for University of California (UC) campuses and California Community College Districts (CCD), covering 451,244 positions, more than $34 billion in wages and over $6 billion in retirement and health contributions, for total compensation exceeding $40.1 billion.

UC campuses report full participation with $33.7 billion in total compensation

All 10 UC campuses and the Office of the President filed complete reports, covering 357,167 positions, more than $29.2 billion in wages and nearly $4.5 billion in retirement and health contributions. UC institutions have maintained a 100 percent reporting rate since voluntarily joining the program in 2013. UCLA reported the most positions at 74,519, followed by UC San Diego at 54,598.

Newsom Signs SCAG-Backed SB 1087, Builders Call It a 'Housing Killer'

Image
Newsom Signs SCAG-Backed SB 1087, Builders Call It a 'Housing Killer'

Irvine, Calif. – October 02, 2026 -- Governor Gavin Newsom signed Senate Bill 1087 on September 30, legislation sponsored by the Southern California Association of Governments (SCAG) that the Building Industry Association of Southern California (BIASC) says will raise housing costs and erode local planning authority across the region.

Builders say the law ties housing production to stricter regional transportation mandates

BIASC opposed the final version of SB 1087 (Cabaldon), arguing it expands regional planning requirements linked to greenhouse-gas reduction and Vehicle Miles Traveled (VMT) targets at a time when California faces a severe housing affordability and production shortfall. The statewide California Building Industry Association had labeled the bill a "Housing Killer."

Africa Business Forum Flags $195B Annual Loss From Resource Abuse

Image
Africa Business Forum Flags $195B Annual Loss From Resource Abuse

Dakar – – October 02, 2026 -- The fifth Africa Business and Human Rights Forum closed in Dakar, Senegal, with more than 1,100 delegates from 45 African countries pressing governments and companies to convert human rights commitments into enforceable business practice, as the continent loses an estimated $195 billion annually to environmental degradation, illicit financial flows and unsustainable resource use.

Delaware, Florida, Nemours Strike $950M Child Health Pact

Image
Delaware, Florida, Nemours Strike $950M Child Health Pact

Wilmington, Delaware – October 02, 2026 -- The Alfred I. duPont Charitable Trust, the State of Delaware, the State of Florida, and The Nemours Foundation have finalized a $950 million agreement spanning 11 years to fund children's health programs in Delaware, under a new entity called the Alfred I. duPont Charitable Fund for Delaware's Children.

New grantmaking fund will direct capital to nonprofit child-health programs statewide

The fund will operate as a separate grantmaking arm, financing nonprofit initiatives focused on children's health and well-being in Delaware. Grantmaking will extend beyond the $950 million, 11-year commitment, and will include at least $237.5 million earmarked specifically for Nemours' Delaware initiatives.

Helitech Wins 10th BBB Torch Award for Ethics

Image
Helitech Wins 10th BBB Torch Award for Ethics

Springfield, Mo. – October 02, 2026 -- Helitech Waterproofing & Foundation Repair has received its 10th Better Business Bureau Torch Award for Ethics, a milestone for the Springfield, Missouri-based specialty contractor.

Helitech secures 10th Torch Award after nearly 40 years in business

The BBB Torch Awards for Ethics recognize companies demonstrating integrity and ethical practices with customers, employees, vendors and communities. Helitech, operating since 1987, has built its service record on foundation repair, basement waterproofing, crawl space repair and concrete repair solutions for homeowners.

Northern Jet Earns IS-BAO Registration for International Flight Safety

Image
Northern Jet Earns IS-BAO Registration for International Flight Safety

Orlando, Fla. – October 02, 2026 -- Northern Jet has achieved Stage 1 registration under the International Standard for Business Aircraft Operations (IS-BAO), a credential issued August 31, 2026 and valid through August 31, 2028.

Charter operator passes three-day audit to secure global safety standard

The registration, developed by the International Business Aviation Council (IBAC), followed an extensive preparation process and a three-day audit examining Northern Jet's flight operations, policies, procedures and Safety Management System. IS-BAO is built on internationally accepted standards for aircraft operations, emphasizing structured safety management, risk identification and organizational accountability.

Vanda Presents Three Imsidolimab Data Sets for Rare Skin Disease GPP at EADV

Image
Vanda Presents Three Imsidolimab Data Sets for Rare Skin Disease GPP at EADV

Washington – October 02, 2026 -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is presenting three new data sets on its monoclonal antibody imsidolimab at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Vienna, Austria, running September 30 through October 3, 2026.

Vanda shows imsidolimab cuts neutrophil levels rapidly in GPP patients

Poster P1769 (Abstract AS-4323) reports a rapid reduction in neutrophils and the neutrophil percentage-to-albumin ratio following imsidolimab treatment in patients with generalized pustular psoriasis (GPP), a rare orphan skin condition.

Immunogenicity data on imsidolimab presented in separate poster

A second poster, P1784 (Abstract AS-2420), details the immunogenicity profile of imsidolimab in GPP patients.